Abstract
The incidence of progressive kidney disease associated with diabetes continues to increase worldwide. Only partial renoprotection is achieved by current standard therapy with angiotensin-converting enzyme inhibitors and/or angiotensin-receptor blockers, increasing the need for novel therapeutic approaches. Experimental studies have provided evidence of a pathogenic role for endothelin-1 (ET-1) and its cognate receptors in the development and progression of diabetic nephropathy. ET-1, mainly through the activation of ETA receptor, contributes to renal cell injury, inflammation, and fibrosis. In animal models of type 1 and type 2 diabetes, ETA-selective antagonists have been shown to provide renoprotective effects, supplying the rationale for clinical trials in patients with diabetic nephropathy with ETA-receptor antagonists administered in addition to renin-angiotensin system blockade.
Original language | English |
---|---|
Pages (from-to) | 188-196 |
Number of pages | 9 |
Journal | Seminars in Nephrology |
Volume | 35 |
Issue number | 2 |
DOIs | |
Publication status | Published - Mar 1 2015 |
Keywords
- Diabetic nephropathy
- Dual inhibition of endothelin-converting enzyme
- Endothelin-receptor antagonists
- Neutral endopeptidase
- Renin-angiotensin system inhibitors
ASJC Scopus subject areas
- Nephrology
- Medicine(all)